Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (295)	8/23/1999 11:10:00 PM
From: Casaubon	Read Replies (1) \| Respond to of 1169

good thread, but for the sake of accuracy: J Acquir Immune Defic Syndr 1999;21:362-370.>> indicate that VX-497 (which is advance IMPDH inhibitor and mycophenolate derivative), currently in PII for psoriasis and HCV, may have other application as broad anti-viral agents. the above statement is not entirely correct. VX-497 is a novel IMPDH inhibitor. It shares no structural similarities with MPA, while it does inhibit the action of the same target enzyme. VX-497 is a wholely owned, Vertex patented entity. PS. I doubt this is driving the price action.